StockData
Cellectis S.A. logo

Cellectis S.A. (CLLS) stock

CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 20, 2026Score 3/30
$1.06+0.02 (+1.92%)

Close on Nov 17, 2026Market cap $106.36MP/E –Yield –

Cellectis operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

For fiscal 2025 it was -$39.40M, down 271.4% from the year before. The highest annual figure on record is $22.99M in fiscal 2024.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$39.40M-271.4%
FY2024Dec 31, 2024$22.99M–
FY2023Dec 31, 2023-$24.75M–
FY2022Dec 31, 2022-$87.44M–
FY2021Dec 31, 2021-$104.56M–
FY2020Dec 31, 2020-$80.26M–
FY2019Dec 31, 2019-$69.14M–
FY2018Dec 31, 2018-$68.14M–
FY2017Dec 31, 2017-$52.33M–
FY2016Dec 31, 2016-$32.71M-1010.9%
FY2015Dec 31, 2015$3.59M–

More Cellectis figures

See a number that looks wrong?